Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mania; Bipolar Disorder
Intervention: Quetiapine Fumarate (Drug); Lithium (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s): Clara Gu, Study Chair, Affiliation: AstraZeneca
Summary
This is a randomised, double blind, double dummy, multicentre, parallel-group study to
compare the efficacy and safety of quetiapine and lithium used as monotherapy in the
treatment of mania in patients hospitalised for an acute manic episode. After given of
informed consent and undergoing screening procedures, the patients will be randomised into
quetiapine or lithium group on Day 1. The efficacy of study treatment on symptoms of mania
will be assessed at Day 28. Patients will not permitted to use any psychoactive or
antipsychotic medications throughout the study period other than those expressly permitted
by the protocol. The patients are required to be hospitalised for the treatment and
assessment defined in the protocol. He/She could be discharged from the hospital after Week
2 (i. e. On Day 15) if the investigator believes that it will be clinical appropriate to
discharge the patient, that the patient is not suicidal or homicidal, and that the patient
could reasonably be expected to continue in the study on an outpatient basis. The patients
discharged after Day 15 will be given sufficient study medication for the period from
discharge to the next visit. At each centre, the same individual will administer a specific
psychiatric assessment for a patient at all study visits in order to reduce variability in
rating scale scoring. Before the initiation of the study, a consistency assessment will be
done among the investigators who conduct the scale assessment in each centre.
Clinical Details
Official title: A Double Dummy & Double Blind, Multicenter, Randomized Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania in Patients With Bipolar Disorder
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Effectiveness of quetiapine fumarate used as monotherapy in treatment of symptoms of acute mania in patients with bipolar disorder by evaluation of the change from baseline in YMRS total score at Day 28 using the last observation carried forward method
Secondary outcome: The effectiveness of quetiapine used as monotherapy to treat symptoms in patients with acute mania by evaluation of YMRS response rate at Day 28 (LOCF).
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Written informed consent for study participation, signed by the patient's legal
guardian.
- Both at screening and at randomization (Day 1), had a YMRS total score of at least
20.
Exclusion Criteria:
- Known intolerance or lack of response to quetiapine or lithium, as judged by the
investigator.
- Known or suspected hypersensitivity to quetiapine or lithium.
Locations and Contacts
Research Sites, Beijing, China
Research Site, Guang Zhou, China
Research Site, Kunming, China
Research Site, Nanjing, China
Research Site, Shanghai, China
Research Site, Wu han, China
Additional Information
Starting date: August 2005
Last updated: December 7, 2010
|